Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL A randomized phase III study of ramucirumab RAM plus docetaxel DOC vs DOC for second line treatment of stage IV non small cell lung cancer NSCLC
Bildiriler > Özet Bildiri · 2015
Yazarlar: L PAZARES, M PEROL, TE CIULEANU, R KOWALYSZYN, M RECK, CR LEWANSKİ, KN SYRİGOS, O ARRİETA, K PRABHASH, K PARK, J PİKİEL, Tuncay GÖKSEL, OS LEE, A ZİMMERMAN, J TREAT, D FERRY, AS MELEMED, GC CARTER, E ALEXANDRİS, EB GARON
51th Annual Meeting of the American Society of Clinical Oncology, Amerika Birleşik Devletleri, Uluslararası, Özet Bildiri, 2015-2015, cilt 33